Vallon Pharmaceuticals Inc
VLON
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
$0.18
55.8% downside
Current Fair Value
55.8% downsideOvervalued by 55.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-1,812,000.00 |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | -1.15 |
| Outstanding Shares | - |
Return
| Return on Equity | -662.82% |
|---|---|
| Return on Assets | -197.60% |
| Return on Invested Capital | -729.22% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.2 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.81 |
| Debt to Equity | 1.22 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vallon Pharmaceuticals Inc
2 employeesVallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The ...